***Background.*** Over the last decade antiretroviral (ARV) regimens have become more effective and better tolerated yielding many options for use in first line therapy. Using data from the CNICS cohort, we explored factors associated with selection of the class of initial ARV regimen.

***Methods.*** CNICS is a network of 8 HIV clinics situated at academic centers in the US. We classified all patients initiating HAART (3 or more drugs) between July 2009 and December 2012 as NNRTI, boosted-PI (PI/r), or raltegravir (InSTI). Measured factors suspected of being associated with regimen choice were explored individually and in 3 separate multivariable logistic regression models with regimen classification as the outcome variable. For each model the referent group was all patients whose initial HAART regimen was not in the classification being modeled.

***Results.*** 1215 patients initiated HAART in the observation period. 650 regimens contained an NNRTI, 455 regimens contained a boosted-PI and 110 regimens contained raltegravir. Median age was 38 years; 34% Black, 57% White, 9% other; 19% Hispanic; 88% male; 67% MSM; 14% IVDU; 25% VL \>100K; 16% HCV infected; and 65% had \> 2 co-morbid conditions.

  ---------------------------------------------------------------------------------------------------
                                          Model 1: NNRTI      Model 2:\           Model 3: InSTI
                                                              PI/r                
  --------------------------------------- ------------------- ------------------- -------------------
  **Age 37-47 vs 19-36**                  1.0 (0.7-1.3)       0.9 (0.7-1.2)       1.3 (0.8-2.2)

  **Age 48-75 vs 19-36**                  1.0 (0.7-1.4)       0.9 (0.6-1.2)       1.4 (0.8-2.4)

  **Female vs MSM**                       **0.5 (0.3-0.7)**   **2.1 (1.5-3.0)**   1.1 (0.7-2.0)

  **Heterosexual Male vs MSM**            0.9 (0.6-1.3)       1.1 (0.8-1.6)       1.3 (0.8-2.3)

  **Prior ART Exposure**                  0.5 (0.2-1.2)       1.3 (0.6-2.9)       1.7 (0.6-4.7)

  **Liver-HCV Dx**                        **0.6 (0.4-0.9)**   1.3 (0.9-1.8)       1.4 (0.8-2.3)

  **Psych Depression Dx**                 **0.6 (0.5-0.8)**   **1.5 (1.2-1.9)**   **1.9 (1.2-3.0)**

  **Cardiovascular/Cerebrovascular Dx**   0.9 (0.5-1.6)       0.8 (0.4-1.6)       **2.7 (1.2-5.7)**

  **Diabetes Dx**                         0.9 (0.5-1.6)       0.9 (0.5-1.7)       1.7 (0.8-3.5)

  **Hypertension Dx**                     0.9 (0.7-1.2)       1.0 (0.7-1.4)       1.5 (0.9-2.4)
  ---------------------------------------------------------------------------------------------------

***Conclusion.*** The choice of initial regimen is associated with several demographic and clinical factors, which is sometimes referred to as 'channeling.' In this study, patients with underlying psychiatric conditions were less likely to receive an NNRTI, while those with CVD were more likely to receive raltegravir. As more choices for HIV therapy become available, factors that impact initial regimen selection will likely become even more heterogeneous over time.
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